Pub Date : 2021-01-01DOI: 10.37421/1747-0862.2021.15.470
A. Sobko
Sch-9 appears to be the Saccharomyces cerevisiae homolog of protein kinase B and S6 kinase and is involved in the control of numerous nutrient-sensitive processes, including regulation of cell size, cell cycle progression, and stress resistance. Sch-9 has also been implicated in the regulation of replicative and chronological life span. The availability of data from global studies of protein-protein interactions now makes it possible to predict and validate functional connections between Sch-9, its putative substrates, and other proteins. Sch-9 appears to be involved in control of biosynthetic and catabolic pathways. Thus, the analysis of Sch-9-associated proteins indicates that this kinase may be involved in regulation of protein synthesis. Sch-9 forms a complex with, and, presumably, phosphorylates starvation- and stress-induced protein kinase GCN2, which, in turn, phosphorylates translation initiation factor eIF2-alpha. Sch-9 also interacts with translation factors Arc1, Pab1 and prion-like protein Sup-35. Thus, Sch-9 may be part of the mechanism that relays availability of nutrients to utilization of glucose and to the rates of protein synthesis. One of the interesting outcomes of the proteome-wide analysis of protein-protein interactions in yeast is the finding that Sch-9 associates with Shp1, Cdc48, and Ufd1, which form a complex responsible for the recognition and targeting of ubiquitinated proteins to the proteasome for degradation. It is unknown and remains to be elucidated, whether mammalian paralogues of Sch-9 are also associated with the proteins involved in translation/protein synthesis and proteasomal degradation.
{"title":"Cell Systems Biology of Translation Factors and Proteasome-Targeted Protein Complexes Associated with AGC Kinase Sch 9","authors":"A. Sobko","doi":"10.37421/1747-0862.2021.15.470","DOIUrl":"https://doi.org/10.37421/1747-0862.2021.15.470","url":null,"abstract":"Sch-9 appears to be the Saccharomyces cerevisiae homolog of protein kinase B and S6 kinase and is involved in the control of numerous nutrient-sensitive processes, including regulation of cell size, cell cycle progression, and stress resistance. Sch-9 has also been implicated in the regulation of replicative and chronological life span. The availability of data from global studies of protein-protein interactions now makes it possible to predict and validate functional connections between Sch-9, its putative substrates, and other proteins. Sch-9 appears to be involved in control of biosynthetic and catabolic pathways. Thus, the analysis of Sch-9-associated proteins indicates that this kinase may be involved in regulation of protein synthesis. Sch-9 forms a complex with, and, presumably, phosphorylates starvation- and stress-induced protein kinase GCN2, which, in turn, phosphorylates translation initiation factor eIF2-alpha. Sch-9 also interacts with translation factors Arc1, Pab1 and prion-like protein Sup-35. Thus, Sch-9 may be part of the mechanism that relays availability of nutrients to utilization of glucose and to the rates of protein synthesis. One of the interesting outcomes of the proteome-wide analysis of protein-protein interactions in yeast is the finding that Sch-9 associates with Shp1, Cdc48, and Ufd1, which form a complex responsible for the recognition and targeting of ubiquitinated proteins to the proteasome for degradation. It is unknown and remains to be elucidated, whether mammalian paralogues of Sch-9 are also associated with the proteins involved in translation/protein synthesis and proteasomal degradation.","PeriodicalId":88269,"journal":{"name":"Journal of molecular and genetic medicine : an international journal of biomedical research","volume":"15 1","pages":"1-3"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70041369","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-01-01DOI: 10.37421/1747-0862.2021.15.471
Ray, Deo Svs, K. Luthra, S. Mathur, An, Ashok Sharma
The mainstay in the management of advanced epithelial ovarian cancer is platinum-based chemotherapy and complete cytoreductive surgery. Despite this, about two-thirds of patients have disease recurrence mostly within the peritoneal cavity. HIPEC (Hyperthermic Intraperitoneal Chemotherapy) is a modality that delivers cell-cycle non-specific chemotherapeutic agents along with heat 41°C to 43°C into the peritoneal cavity. HIPEC is done intra-operatively after achieving complete cytoreduction (which means after removal of all the tumor deposits more than 2.5 mm). Ovarian cancer is associated with the frequent finding of tumor-infiltrating lymphocytes in their tissue microenvironment. Especially studies have shown that ovarian cancer evades immune surveillance by higher expression of FOXP3 T cells. HIPEC has been used in the treatment of primary and recurrent tumors. In this review, we discuss how the significance of HIPEC on genetics and immunology of these patients with cancer have provided unique insights into the molecular and cellular basis of Treg cells. Studies of HIPEC and its association with Tregs cells should make it possible to increase the paucity of immuno- therapeutic modalities of most human cancer at an unprecedented level of molecular and cellular precision. The predictive, preventive, and therapeutic implications of these studies of HIPEC in relation to immunity in EOC may extend to patients with other peritoneal carcinomatosis.
{"title":"Molecular Linking of HIPEC (Hyperthermic Intraperitoneal Chemotherapy) and Tregs (Regulatory T- cells) in Advanced Epithelial Ovarian Cancer - A Review","authors":"Ray, Deo Svs, K. Luthra, S. Mathur, An, Ashok Sharma","doi":"10.37421/1747-0862.2021.15.471","DOIUrl":"https://doi.org/10.37421/1747-0862.2021.15.471","url":null,"abstract":"The mainstay in the management of advanced epithelial ovarian cancer is platinum-based chemotherapy and complete cytoreductive surgery. Despite this, about two-thirds of patients have disease recurrence mostly within the peritoneal cavity. HIPEC (Hyperthermic Intraperitoneal Chemotherapy) is a modality that delivers cell-cycle non-specific chemotherapeutic agents along with heat 41°C to 43°C into the peritoneal cavity. HIPEC is done intra-operatively after achieving complete cytoreduction (which means after removal of all the tumor deposits more than 2.5 mm). Ovarian cancer is associated with the frequent finding of tumor-infiltrating lymphocytes in their tissue microenvironment. Especially studies have shown that ovarian cancer evades immune surveillance by higher expression of FOXP3 T cells. HIPEC has been used in the treatment of primary and recurrent tumors. In this review, we discuss how the significance of HIPEC on genetics and immunology of these patients with cancer have provided unique insights into the molecular and cellular basis of Treg cells. Studies of HIPEC and its association with Tregs cells should make it possible to increase the paucity of immuno- therapeutic modalities of most human cancer at an unprecedented level of molecular and cellular precision. The predictive, preventive, and therapeutic implications of these studies of HIPEC in relation to immunity in EOC may extend to patients with other peritoneal carcinomatosis.","PeriodicalId":88269,"journal":{"name":"Journal of molecular and genetic medicine : an international journal of biomedical research","volume":"543 1","pages":"1-8"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70041384","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-01-01DOI: 10.37421/1747-0862.2021.15.478
B. Rita
{"title":"Editorial Note for Gene Therapeutics","authors":"B. Rita","doi":"10.37421/1747-0862.2021.15.478","DOIUrl":"https://doi.org/10.37421/1747-0862.2021.15.478","url":null,"abstract":"","PeriodicalId":88269,"journal":{"name":"Journal of molecular and genetic medicine : an international journal of biomedical research","volume":"15 1","pages":"1-1"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70041983","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-01-01DOI: 10.37421/1747-0862.2021.15.479
B. Rita
{"title":"Editorial Note for Medicinal Biotechnology","authors":"B. Rita","doi":"10.37421/1747-0862.2021.15.479","DOIUrl":"https://doi.org/10.37421/1747-0862.2021.15.479","url":null,"abstract":"","PeriodicalId":88269,"journal":{"name":"Journal of molecular and genetic medicine : an international journal of biomedical research","volume":"15 1","pages":"1-1"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70061413","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-01-01DOI: 10.37421/1747-0862.2021.15.499
B. Rita
{"title":"Editorial Note on Molecular Genetics and Genomic Medicine","authors":"B. Rita","doi":"10.37421/1747-0862.2021.15.499","DOIUrl":"https://doi.org/10.37421/1747-0862.2021.15.499","url":null,"abstract":"","PeriodicalId":88269,"journal":{"name":"Journal of molecular and genetic medicine : an international journal of biomedical research","volume":"15 1","pages":"1-1"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70061568","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-01-01DOI: 10.37421/1747-0862.2021.15.501
P. Chakraborty, A. Chakraborty
Various microorganisms e.g., bacteria, fungi and higher organism e.g., plant during their metabolism produces both primary and secondary metabolites, needed for their survival and defense. Often these secondary metabolites are being used in drug discovery. The genes for the enzymes of these secondary metabolic pathways are generally grouped together as biosynthetic gene clusters (BGCs) and hidden away in organism’s genome. Genome mining of the unexplored microbes, medicinal plants, and underexplored human microbiota with emerging genomics research involving next-generation sequencing technology along with bioinformatics tools like anti-SMASH (antibiotics and Secondary Metabolite Analysis Shell), planti-SMASH, may help in finding many BGCs and subsequently in the discovery of many new drugs in future.
{"title":"Biosynthetic Gene Clusters in Organism: The Sole Source of New Drug Discovery","authors":"P. Chakraborty, A. Chakraborty","doi":"10.37421/1747-0862.2021.15.501","DOIUrl":"https://doi.org/10.37421/1747-0862.2021.15.501","url":null,"abstract":"Various microorganisms e.g., bacteria, fungi and higher organism e.g., plant during their metabolism produces both primary and secondary metabolites, needed for their survival and defense. Often these secondary metabolites are being used in drug discovery. The genes for the enzymes of these secondary metabolic pathways are generally grouped together as biosynthetic gene clusters (BGCs) and hidden away in organism’s genome. Genome mining of the unexplored microbes, medicinal plants, and underexplored human microbiota with emerging genomics research involving next-generation sequencing technology along with bioinformatics tools like anti-SMASH (antibiotics and Secondary Metabolite Analysis Shell), planti-SMASH, may help in finding many BGCs and subsequently in the discovery of many new drugs in future.","PeriodicalId":88269,"journal":{"name":"Journal of molecular and genetic medicine : an international journal of biomedical research","volume":"15 1","pages":"1-3"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70061612","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-01-01DOI: 10.37421/1747-0862.2021.15.485
R. Badigeru
{"title":"Editorial Note for Integrative Medicine","authors":"R. Badigeru","doi":"10.37421/1747-0862.2021.15.485","DOIUrl":"https://doi.org/10.37421/1747-0862.2021.15.485","url":null,"abstract":"","PeriodicalId":88269,"journal":{"name":"Journal of molecular and genetic medicine : an international journal of biomedical research","volume":"15 1","pages":"1-1"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70061786","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-01-01DOI: 10.37421/1747-0862.2021.15.494
Jiang Sw
{"title":"Editorial Note on COVID-19: Coronavirus Vaccines","authors":"Jiang Sw","doi":"10.37421/1747-0862.2021.15.494","DOIUrl":"https://doi.org/10.37421/1747-0862.2021.15.494","url":null,"abstract":"","PeriodicalId":88269,"journal":{"name":"Journal of molecular and genetic medicine : an international journal of biomedical research","volume":"15 1","pages":"1-1"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70061917","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-01-01DOI: 10.37421/1747-0862.2021.15.476
S. Varela-Rodríguez, Caceres-Pajuelo Je, S. Jl
Background: Musculoskeletal disorders are a leading cause of disability and loss of quality of life with a great economic impact. Percutaneous electrolysis is a minimally invasive technique with emerging evidence related to these pathologies. Objective: To examine the effectiveness of percutaneous electrolysis for musculoskeletal pain. Methods: A randomized clinical trials concerning percutaneous electrolysis were searched in the following electronic databases: PubMed, PEDro, CINAHL, MEDLINE, Scopus, Web of Science, Cochrane Library and ScienceDirect. Methodological quality was evaluated according to PEDro score. Risk of bias assessment was conducted using the Cochrane RoB 2 tool. These procedures were carried out by two independent researchers, with the participation of a third reviewer in case of disagreement. Results: Electronic databases searches identified a total of 175 results. After the study selection procedure, 7 studies published from 2015 to 2018 were finally included in the present review. These articles involved a total of 407 patients with different musculoskeletal disorders. Clinical outcomes were evaluated for pain and disability, usually reporting greater improvements in the group with percutaneous electrolysis. The mean score of PEDro scale was 7 points and overall risk of bias was generally reported as high. Conclusion: Percutaneous electrolysis appears to be an effective therapy for the improvement of pain and disability in patients with musculoskeletal disorders. However, the heterogeneity and the high risk of bias of the included studies should be taken into account. Further research is warranted to standardise percutaneous electrolysis application and generate protocols that would improve clinical outcomes.
背景:肌肉骨骼疾病是导致残疾和生活质量下降的主要原因，具有巨大的经济影响。经皮电解是一种微创技术，与这些病理相关的证据越来越多。目的:探讨经皮电解法治疗骨骼肌疼痛的疗效。方法:在PubMed、PEDro、CINAHL、MEDLINE、Scopus、Web of Science、Cochrane Library和ScienceDirect等电子数据库中检索与经皮电解相关的随机临床试验。根据PEDro评分评价方法学质量。偏倚风险评估采用Cochrane RoB 2工具进行。这些程序由两名独立的研究人员进行，如果有不同意见，第三位审稿人也会参与。结果:电子数据库检索共鉴定出175个结果。经过研究选择程序，2015年至2018年发表的7项研究最终纳入本综述。这些文章共涉及407名患有不同肌肉骨骼疾病的患者。临床结果评估疼痛和残疾，通常报告经皮电解组有较大改善。PEDro量表的平均得分为7分，总体偏倚风险普遍较高。结论:经皮电解法是改善肌肉骨骼疾病患者疼痛和残疾的有效方法。然而，应考虑纳入研究的异质性和高偏倚风险。进一步的研究是必要的，以规范经皮电解应用和制定方案，将改善临床结果。
{"title":"Percutaneous Electrolysis in Patients with Musculoskeletal Disorders: A Systematic Review","authors":"S. Varela-Rodríguez, Caceres-Pajuelo Je, S. Jl","doi":"10.37421/1747-0862.2021.15.476","DOIUrl":"https://doi.org/10.37421/1747-0862.2021.15.476","url":null,"abstract":"Background: Musculoskeletal disorders are a leading cause of disability and loss of quality of life with a great economic impact. Percutaneous electrolysis is a minimally invasive technique with emerging evidence related to these pathologies. Objective: To examine the effectiveness of percutaneous electrolysis for musculoskeletal pain. Methods: A randomized clinical trials concerning percutaneous electrolysis were searched in the following electronic databases: PubMed, PEDro, CINAHL, MEDLINE, Scopus, Web of Science, Cochrane Library and ScienceDirect. Methodological quality was evaluated according to PEDro score. Risk of bias assessment was conducted using the Cochrane RoB 2 tool. These procedures were carried out by two independent researchers, with the participation of a third reviewer in case of disagreement. Results: Electronic databases searches identified a total of 175 results. After the study selection procedure, 7 studies published from 2015 to 2018 were finally included in the present review. These articles involved a total of 407 patients with different musculoskeletal disorders. Clinical outcomes were evaluated for pain and disability, usually reporting greater improvements in the group with percutaneous electrolysis. The mean score of PEDro scale was 7 points and overall risk of bias was generally reported as high. Conclusion: Percutaneous electrolysis appears to be an effective therapy for the improvement of pain and disability in patients with musculoskeletal disorders. However, the heterogeneity and the high risk of bias of the included studies should be taken into account. Further research is warranted to standardise percutaneous electrolysis application and generate protocols that would improve clinical outcomes.","PeriodicalId":88269,"journal":{"name":"Journal of molecular and genetic medicine : an international journal of biomedical research","volume":"15 1","pages":"1-7"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70041844","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-01-01DOI: 10.37421/1747-0862.2021.15.477
Srivastava Dsl, K. Mittal, P. Jindal, A. Kumar
Objectives: Glutathione S-transferases (GSTs) enzymes play an important role in the xenobiotic biotransformation of endogenous or exogenous toxicants and thought to protect the airways from oxidative stress, inflammation, and genotoxicity. Polymorphisms in the GST genes may lead to an increased imbalance in antioxidant systems and may influence the pathogenesis of asthma. We examined the association of the GST gene polymorphism to ascertain whether high-risk genotypes of GSTM1/GSTT1 could influence the susceptibility to childhood asthma in the N orth Indian population. Methods: The study constituted of 100 childhood asthmatic cases and 180 age-matched controls. The GSTT1 and GSTM1 null genotypes were identified by multiplex PCR in peripheral blood DNA samples. Statistical analysis was done by using SPSS 20.0 soft ware. Results: No association was seen either the null genotype of the GSTM1 or GSTTT1 (P > 0.05); however, in atopy patients significant association were observed with null genotype of GSTT1 (OR=2.67; P<0.05) for risk of child hood asthma. In combined analysis of GSTM1/GSTT1, presence of null genotypes of GSTM1 G P<0.05) compared to positive genotypes of GSTM1 and GSTT1. When compared among gender, GSTT1 null genotype was found to be statistically significant in male (OR=2.71; P<0.005) as compared to female childhood asthmatic patients. Conclusion: In conclusion, null genotype of GSTT1 exhibits significant association for the risk of childhood asthma, especially in disease predisposition and initiation.
{"title":"Polymorphism of Glutathione Sand#8209;Transferase M1 and T1 Genes and Susceptibility to Childhood Asthma: A Study from North India","authors":"Srivastava Dsl, K. Mittal, P. Jindal, A. Kumar","doi":"10.37421/1747-0862.2021.15.477","DOIUrl":"https://doi.org/10.37421/1747-0862.2021.15.477","url":null,"abstract":"Objectives: Glutathione S-transferases (GSTs) enzymes play an important role in the xenobiotic biotransformation of endogenous or exogenous toxicants and thought to protect the airways from oxidative stress, inflammation, and genotoxicity. Polymorphisms in the GST genes may lead to an increased imbalance in antioxidant systems and may influence the pathogenesis of asthma. We examined the association of the GST gene polymorphism to ascertain whether high-risk genotypes of GSTM1/GSTT1 could influence the susceptibility to childhood asthma in the N orth Indian population. Methods: The study constituted of 100 childhood asthmatic cases and 180 age-matched controls. The GSTT1 and GSTM1 null genotypes were identified by multiplex PCR in peripheral blood DNA samples. Statistical analysis was done by using SPSS 20.0 soft ware. Results: No association was seen either the null genotype of the GSTM1 or GSTTT1 (P > 0.05); however, in atopy patients significant association were observed with null genotype of GSTT1 (OR=2.67; P<0.05) for risk of child hood asthma. In combined analysis of GSTM1/GSTT1, presence of null genotypes of GSTM1 G P<0.05) compared to positive genotypes of GSTM1 and GSTT1. When compared among gender, GSTT1 null genotype was found to be statistically significant in male (OR=2.71; P<0.005) as compared to female childhood asthmatic patients. Conclusion: In conclusion, null genotype of GSTT1 exhibits significant association for the risk of childhood asthma, especially in disease predisposition and initiation.","PeriodicalId":88269,"journal":{"name":"Journal of molecular and genetic medicine : an international journal of biomedical research","volume":"15 1","pages":"1-5"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70041858","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：